Candid Therapeutics Launches With $370 Million In Funding
By Amit Chowdhry ● Sep 9, 2024
Candid Therapeutics, a biotechnology company focused on developing potentially transformative drugs to address autoimmune diseases, announced it has officially launched today. To drive development and position Candid to become the leader in TCE antibodies for autoimmune diseases, Candid also acquired Vignette Bio and TRC 2004 through a simultaneous three-way merger and multi-step financing. This acquisition integrates two cutting-edge bispecific TCEs. In connection with the merger, Candid has successfully raised over $370 million in capital from an extensive roster of investors, including a recently completed financing co-led by Venrock Healthcare Capital Partners, Fairmount, TCGX, and venBio Partners.